Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies

@article{Bornstein2009DevelopmentOA,
  title={Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies},
  author={Gadi Gazit Bornstein and Christophe Qu{\'e}va and M. Tabrizi and Anne van Abbema and Carlos Chavez and Ping F. Wang and Orit Foord and Kiran Ahluwalia and Naomi Laing and Sandhya Raja and Shenghua Wen and Larry L. Green and Xiaodong Yang and Carl D. Webster and Ross A Stewart and David H Blakey},
  journal={Investigational New Drugs},
  year={2009},
  volume={28},
  pages={561-574}
}
Despite the widespread use of rituximab, a chimeric monoclonal antibody with demonstrated efficacy in the treatment of non-Hodgkin’s lymphomas, there is a recognized need to develop new agents with improved efficacy. Towards this end, using XenoMouse® technology, a fully human IgG1 anti-CD20 monoclonal antibody was generated. This antibody, denoted mAb 1.5.3, evoked enhanced pro-apoptotic activity in vitro, as compared to rituximab, in the Ramos lymphoma cell line. Also, mAb 1.5.3 mediated both… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 39 references

Novel 3 rd generation humanized type II CD20 antibody with glycoengineered Fc and modified elbow hinge for enhanced ADCC and superior apoptosis induction

P Umana, E Moessner, P Bruenker
ASH Annual Meeting Abstracts • 2006
View 1 Excerpt

Similar Papers

Loading similar papers…